IDEAYA Biosciences - Margin dodolan resik IDYA

IDEAYA Biosciences develops precision oncology drugs, mitigating risks through a broad portfolio and alliances with the IT sector. US-based laboratories are implementing genetics-based treatment methods. Net profit returns on sales demonstrate efficiency dynamics, where the -1149.60 indicator determines the parameter status. However, the absence of commercial products leads to negative cash flow and a reliance on investments.
IDEAYA Bio - rincian analitis lan metrik utama (IDYA)

This indicator is calculated as the ratio of net income to revenue, measuring the efficiency of converting each dollar of sales into final income after deducting all operating and financial expenses. For IDEAYA Biosciences (IDYA), a negative net profit margin reflects a stage of intensive capital burn on oncology clinical trials in the absence of full-scale commercial product realization.